Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Public ClinicalTrials.gov record NCT06625320. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
RASolute 302: A Phase 3 Multicenter, Open-label, Randomized Study of Daraxonrasib (RMC-6236) Versus Investigator's Choice of Standard of Care Therapy in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.
Study identification
- NCT ID
- NCT06625320
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 500 participants
Conditions and interventions
Interventions
- RMC-6236 Drug
- Gemcitabine Drug
- nab-paclitaxel Drug
- Irinotecan Drug
- Liposomal irinotecan Drug
- 5-fluorouracil Drug
- leucovorin Drug
- Oxaliplatin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 16, 2024 (Actual)
- Primary completion
- Jun 2026 (Estimated)
- Completion
- Dec 2027 (Estimated)
- Last update posted
- Jun 2, 2026
2024 – 2027
United States locations
- U.S. sites
- 37
- U.S. states
- 22
- U.S. cities
- 34
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner MD Anderson Cancer Center | Gilbert | Arizona | 85234 | — |
| Mayo Clinic Cancer Center - Phoenix | Phoenix | Arizona | 85054 | — |
| City of Hope-Duarte | Duarte | California | 91010 | — |
| Cedars-Sinai Medical Center | Los Angeles | California | 90048 | — |
| UCLA | Los Angeles | California | 90095 | — |
| UC San Diego Health Moores Cancer Center | San Diego | California | 92037 | — |
| Mission Hall UCSF | San Francisco | California | 94158 | — |
| Rocky Mountain Cancer | Aurora | Colorado | 80012 | — |
| Mayo Clinic Cancer Center - Florida | Jacksonville | Florida | 32224 | — |
| University of Miami Sylvester Comprehensive Cancer Center | Miami | Florida | 33136 | — |
| Cancer Care Centers of Brevard Inc | Palm Bay | Florida | 32909 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| The Queen's Medical Center | Honolulu | Hawaii | 96813 | — |
| The University of Chicago Medical Center | Chicago | Illinois | 60637 | — |
| Johns Hopkins | Baltimore | Maryland | 21287 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Mayo Clinic Cancer Center - Rochester | Rochester | Minnesota | 55905 | — |
| Washington University | St Louis | Missouri | 63110 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| NYU Lagone Health | New York | New York | 10016 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10022 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| University of Cincinnati Medical Center | Cincinnati | Ohio | 45219 | — |
| Stephenson Cancer Center | Oklahoma City | Oklahoma | 73104 | — |
| Oregon Health and Science University | Portland | Oregon | 97239 | — |
| Abramson Cancer Center Clinical Research Unit | Philadelphia | Pennsylvania | 19104 | — |
| UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | — |
| Sarah Cannon Research Institute (Tennessee) | Nashville | Tennessee | 37203 | — |
| Texas Oncology Sammons | Dallas | Texas | 75246 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Texas Oncology - Central South | Irving | Texas | 75063 | — |
| Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | — |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | — |
| Fred Hutchinson Cancer Center | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 23 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06625320, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 2, 2026 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06625320 live on ClinicalTrials.gov.